Background Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolut... HC Detke,DP Mcdonnell,E Brunner,... - 《Bmc Psychiatry》 被引量: 151发表: 2010年 Monitoring of olanzapine in serum by liquid chromatogr...
Olanzapine pamoate (olanzapine long-acting injection [OLAI]; Zypadhera; Zyprexa Relprevv) is the intramuscular depot formulation of the atypical antipsycho... James,E.,Frampton - 《Drugs》 被引量: 34发表: 2010年 Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent The nove...
Methods: Female sham-operated or ovariectomized rats were treated with a single injection of olanzapine depot formulation. Food intake, body weight, plasma lipids, lipogenic gene expression, energy expenditure, and thermogenic markers including brown adipose tissue uncoupling protein 1 protein levels were...
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005 ;23(1... DD Graeve,A Smet,A Mehnert,... - 《Pharmacoeconomics》 被引量: 82发表: 2005年 Cost-effectiveness of olanzapine long-acting injection ...
Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizoph... Comparing the treatment options shows that in view of clinical efficacy and cost saving effects, long-acting risperidone is the dominant therapy...
Unfortunately, the clinical utility of atypical antipsychotics is limited by concerns regarding their side effects of weight gain and metabolic disturbance [3–5]. The development of weight gain and metabolic adverse effects could further lead to increased morbidity and mortality, along with poor ...